Humoral immune response to p21(WAF1/CIP1) in tumor patients, non-tumorous patients and healthy blood donors

Cancer Letters

Volumn 137, Issue 2, 1999, Pages 151-157

  Selter, Helga ^a   Schmidt, Gabriele ^a   Villena Heinsen, Carlos ^b   Montenarh, Mathias ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Growth suppressor protein; mdm2 autoantibodies; p21(WAF1 CIP1); p53; Tumor marker

Indexed keywords

AUTOANTIBODY; CANCER ANTIBODY; PROTEIN MDM2; TUMOR MARKER;

ARTICLE; BLOOD DONOR; BREAST CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; OVARY CANCER; PRIORITY JOURNAL; SEROLOGY; UTERINE CERVIX CANCER;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; BREAST DISEASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEROLOGIC TESTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032960331     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00356-5     Document Type: Article

References (27)

1. Ben-Mahrez K., Sorokine I., Thierry D., Kawasumi T., Ishir S.R.S., Kohiyama M. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int. J. Cancer. 46:1990;35-38.
2. Canman C.E., Gilmer T.M., Coutts S.B., Kastan M.B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9:1995;600-611.
3. Waf1/Cip1 with PCNA. Oncogene. 11:1995;1931-1937.
4. 1 arrest. Cell. 76:1994;1013-1023.
5. 1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
6. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
7. CIP1/WAF1 protein accumulation in head-and-neck cancer. Int. J. Cancer. 74:1997;383-389.
8. Götz C., Wagner P., Issinger O.G., Montenarh M. p21WA1/CIP1 interacts with protein kinase CK2. Oncogene. 13:1996;391-398.
9. Harlow E., Crawford L.V., Pim D.C., Williamson N.M. Monoclonal antibodies specific for the SV40 tumor antigens. J. Virol. 39:1981;861-869.
10. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1994;805-816.
11. WAF1/Cip1 in human brain tumors. Oncogene. 11:1995;2021-2028.
12. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature. 371:1994;534-537.
13. Marchetti A., Buttitta F., Pellegrini S., Bertacca G., Lori A., Bevilacqua G. Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinomas: a polymorphism at codon 31. Int. J. Oncol. 6:1995;187-189.
14. Marx J. New link found between p53 and DNA repair. Science. 266:1994;1321-1322.
15. Montenarh M., Götz C. p53 autoantibodies and human malignancies. Cancer Mol. Biol. 4:1997;991-1010.
16. Montenarh M., Herrmann C.P.E., Höher D., Selter H. Biochemical properties of p53 in a human tumor cell line. Cancer Mol. Biol. 1:1994;121-131.
17. Ohashi K., Nemoto T., Eishi Y., Matsuno A., Nakamura K., Hirokawa K. Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas. Virchow's Arch. Int. J. Pathol. 430:1997;389-395.
18. Papandreou C.N., Bogenrieder T., Scher H.I., Albino A.P., Nanus D.M. Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell line. Int. J. Oncol. 8:1996;1237-1241.
19. Picksley S.M., Lane D.P. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53. BioEssays. 15:1993;689-690.
20. Rotter V., Witte O.N., Coffman R., Baltimore D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, p50. J. Virol. 36:1980;547-555.
21. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52:1992;6380-6384.
22. Selter H., Amela-Neuschwander S., Villena-Heinsen C., Montenarh M. Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases. Cancer Lett. 96:1995;111-115.
23. Selter H., Montenarh M. The emerging picture of p53. Int. J. Biochem. 26:1994;145-154.
24. Shimizu T., Miwa W., Nakamori S., Ishikawa O., Konishi Y., Sekiya T. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn. J. Cancer Res. 87:1996;275-278.
25. Shiohara M., El Deiry W.S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D.-L., Koeffler H.P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
26. Sorokine I., Ben M.K., Bracone A., Thierry D., Ishii S., Imamoto F., Kohiyama M. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int. J. Cancer. 47:1991;665-669.
27. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260:1996;623-637.